1Day Sooner
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
1Day Sooner is a nonprofit that advocates for people who want to participate in medical research, in particular human challenge trials. 1Day Sooner began in March 2020 in response to the COVID-19 pandemic, organizing people willing to volunteer in human challenge trials as a means to speed development of vaccines against the disease.
1Day Sooner's advocacy for COVID-19 challenge trials was met with both support and opposition among the public, scientists, and bioethicists. COVID-19 challenge trials were ultimately implemented in the United Kingdom. 1Day Sooner also conducts advocacy work on public health policy and for challenge trials in other infectious diseases.
1Day Sooner is a nonprofit that advocates for people who want to participate in medical research, in particular human challenge trials. 1Day Sooner began in March 2020 in response to the COVID-19 pandemic, organizing people willing to volunteer in human challenge trials as a means to speed development of vaccines against the disease.
1Day Sooner's advocacy for COVID-19 challenge trials was met with both support and opposition among the public, scientists, and bioethicists. COVID-19 challenge trials were ultimately implemented in the United Kingdom. 1Day Sooner also conducts advocacy work on public health policy and for challenge trials in other infectious diseases.
Covid-19 challenge trials
1Day Sooner was established by Josh Morrison, a founder of kidney donation group Waitlist Zero, and Sophie Rose, a Stanford biology graduate. Morrison and Rose were motivated to do so after reading about how human challenge trials in young, healthy volunteers could potentially accelerate COVID-19 vaccine development, and set up an initial signup website in March 2020 for people interested in being a research subject in COVID-19 human challenge studies.
By October 2020, over 38,500 had expressed interest in participation via the website. A survey study of 1Day Sooner prospective volunteers found that they were more likely to display altruistic behaviors, such as charitable donations or blood donation, than a control group.
The study argued that this potentially addressed concerns of some bioethicists regarding the potential exploitation of volunteers. 1Day Sooner viewed challenge trials as a means to promote the development of multiple vaccines, particularly ones accessible in low-income countries, as well as gain more insight into COVID-19 immunity.
If early vaccine candidates in development in 2020 had turned out to be ineffective, moreover, 1Day Sooner argued challenge trials could have been used to prioritize most promising vaccines from remaining candidates. The organization held that if challenge trials could result in a benefit for society, informed individuals should be allowed the freedom to volunteer themselves, even in the face of potentially serious risks.
The government of the United Kingdom announced in October 2020 that it would sponsor COVID-19 human challenge trials. 1Day Sooner called for the COVID-19 study protocols to be published before the studies began recruiting.
In August 2020, the United States government made preparations to manufacture a strain of the virus to be used in potential human challenge trials partially as a result of advocacy by 1Day Sooner. As of 2022, such trials have not been implemented in the United States.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1367789048 under CC BY-SA 4.0; modifications have been made.